Surrogate Decision Making for Genetic Testing for Alzheimer Disease
- 1 January 1999
- journal article
- review article
- Published by Mary Ann Liebert Inc in Genetic Testing
- Vol. 3 (1) , 93-97
- https://doi.org/10.1089/gte.1999.3.93
Abstract
Genetic tests are commercially available for the purpose of aiding in the differential diagnosis of Alzheimer disease among patients with dementia. Such patients often lack the mental capacity to consent to or reject such testing. If genetic testing is to be undertaken, it is important legally and ethically to consider who should participate in the decision to test. State law and the patient's previously expressed wishes will determine which individual should serve as the surrogate decision maker. Other family members should be included in the discussion of the decision, and their assent to the surrogate's decision should be sought.Keywords
This publication has 12 references indexed in Scilit:
- Special Issues in Genetic Testing for Alzheimer DiseaseGenetic Testing, 1999
- Barriers to Obtaining Consent in Dementia Research: Implications for Surrogate Decision‐MakingJournal of the American Geriatrics Society, 1998
- Durable power of attorney and informed consent with Alzheimer's disease patients: a clinical studyAmerican Journal of Psychiatry, 1997
- How well is the patient self-determination act working?: An early assessmentThe American Journal of Medicine, 1993
- Beyond Advance Directives — Health Care Surrogate LawsNew England Journal of Medicine, 1992
- Litigating Life and DeathHarvard Law Review, 1988
- Informed Consent for Major Medical Treatment of Mentally Disabled PeopleNew England Journal of Medicine, 1988
- Initiating and Withdrawing Life SupportNew England Journal of Medicine, 1988
- A Surrogate System for Informed ConsentJAMA, 1975